Overview

About this study

Novel, high-performance genomic technologies now allow detection of signals from cancers in the blood, giving rise to a new paradigm of multi-cancer detection (MCD) tests. Blood is inherently well suited for detection of cancer biomarkers as it contains circulating tumor cells and tumor cell-free DNA (cfDNA) that have been “shed” from an occult asymptomatic developing cancer. MCD tests analyze these genomic features of the circulating DNA, distinguish it from background signals and determine a site of tumor origin to guide subsequent testing to establish a firm cancer diagnosis (hopefully pre-symptomatic early stage and highly curable). An effective MCD test should have three features: a reasonably high aggregate sensitivity, coverage of a wide range of tumor types and a very low false-positive rate. There are currently multiple companies with MCD tests in production.

This study proposes a prospective observational registry study involving patients who have undergone clinical MCD testing at Mayo Clinic or referred to Mayo Clinic with MCD test results for further evaluations and management.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Has Mayo Clinic medical record number
  • Has undergone (within last 6 months) or scheduled to undergo a multi-cancer detection test (MCD)
  • Able to provide informed consent,
  • ≥ 21 years old
  • Ability to provide blood sample

Exclusion Criteria

  • Individuals who have situations that would limit compliance with the study requirements,
  • Institutionalized (i.e. Federal Medical Prison)
  • Known pregnancy (self-reported)
  • Currently undergoing active cancer treatment other than adjuvant hormone therapy
  • Invasive cancer diagnosis within the last 3 years

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ryan Hurt, M.D., Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Richard Presutti, D.O., FAAFP

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Niloy Jewel Samadder, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20579945

Mayo Clinic Footer